Survivin is a 16.5 kDa protein and the smallest inhibitor of apoptosis (IAP) so far identified. It is involved in the inhibition of apoptosis and cell division. Survivin expression has been reported at high levels in embryonic tissues, but at low or non-detectable levels in normal tissue. Survivin regulates the G2/M phase of the cell cycle by associating with the mitotic spindle microtubules and directly inhibits Caspase-3 and Caspase-7. Survivin is selectively expressed in the most common human cancers and is associated with clinical tumor progression. It has been proposed as a tumor marker for breast cancer, and Survivin expression has been correlated to clinical outcome in melanoma patients. Down-regulation or loss of Survivin is thought to inhibit the growth of tumor cells. Further, it has been indicated that Survivin epitopes may serve as important targets for anticancer immunotherapy approaches, and that Survivin is a rational target for apoptosis-based cancer therapy. It has also been proposed that Survivin may be used as a universal tumor antigen for immunotherapy.
应用类型
IHC, WB
免疫原
Recombinant human Survivin protein (full length).
来源宿主
Mouse
反应性
该BIRC5 抗体的反应性请参考该产品的说明书
保存建议
Long Term Storage : -20C
其他
Aviva Systems Biology总部位于加利福尼亚州圣迭戈，在中国北京设有办公室，专注于为研究需求提供多克隆和单克隆抗体、ELISA试剂盒、蛋白质和定制服务。Aviva Systems Biology生产了24,000种经过验证的多克隆抗体，并提供近20,000种ELISA试剂盒，定制实验室服务包括蛋白表达和纯化、抗体开发，以及ELISA的开发、验证和生产。Aviva Systems Biology为与独特物种和靶标相关的研究提供独特工具，研究领域包括转录因子、癌症、心血管、细胞生物学、DNA损伤和修复、表观遗传学、信号转导、细胞分化、干细胞生物学等等。
